Immunophenotype of Acute Myeloid Leukemia: Correlation with Morphological Characteristics and Therapy Response

Sperling, Christian; Seibt-Jung, H.; Gassmann, W.; Komischke, B.; Sauerland, Christina; Hiddemann, Wolfgang; Löffler, H.; Büchner, Th.; Thiel, E.; Ludwig, Wolf Dieter

doi:10.1007/978-3-642-84895-7_34

Cited by 10 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Myeloid and particularly monocytic differentiation is not accompanied by reliably identifiable markers. CD14 is often negative in cases of acute monocytic and myelomonocytic leukaemias and appears in M1 and M2 subsets (Sperling et al , 1993). Here, we found that leukaemic blasts appearing in M1 and M2 AML patients expressed significantly less PSGL‐1 on their surfaces than mature neutrophils, whereas the amount of PSGL‐1 on monoblasts/promonocytes was not significantly different from mature monocytes.…”

Section: Discussionmentioning

confidence: 99%

Identification of P‐selectin glycoprotein ligand‐1 as a useful marker in acute myeloid leukaemias

Kappelmayer¹,

Kiss

Karászi³

et al. 2001

Br J Haematol

View full text Add to dashboard Cite

Summary.Immunophenotyping is considered to be less valuable in the diagnosis of acute myeloid leukaemias (AML) compared with acute lymphoid leukaemias. Here, we present data on the use of quantitative flow cytometry (QFC) of P-selectin glycoprotein ligand 1 (PSGL-1, CD162) and three-colour immunophenotyping including CD162 staining in the identification of myeloid precursors in AML. Analysis of normal peripheral blood (n 20) and normal bone marrow (n 5) samples and on 20 samples from de novo M1, M2, M4 and M5 AML patients demonstrated that PSGL-1 is differentially expressed on various mature and immature leucocyte subsets. It was found by QFC that neutrophils expressed 26500^4500 and monocytes 47200^9900 copies of PSGL-1 on their surface, whereas AML blasts from M1 and M2 AML patients expressed significantly less PSGL-1 (12 000^5300) than mature neutrophils (P , 0´001). In M4 and M5 leukaemias, however, the amount of PSGL-1 on monocytic precursors is displayed in a fairly broad range that is not significantly different from that of mature monocytes (P 0´084). Using three-colour immunophenotyping PSGL-1-dim staining was co-expressed with CD7 and C34 positivity and PSGL-1 staining intensity on immature myeloid cells paralleled with CD45 expression. This would imply a differential expression of PSGL-1 during myeloid haematopoietic development and suggests that quantification of surface PSGL-1 may aid in differentiating myeloblasts from monoblasts by immunophenotyping in different AML subsets.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of P‐selectin glycoprotein ligand‐1 as a useful marker in acute myeloid leukaemias

Kappelmayer¹,

Kiss

Karászi³

et al. 2001

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…For example, t(8:21), inv(16), chromosome 5 and 7 aberrations, as well as complex karyotypes, were observed more frequently in CD34+ AML [49,121), and CD 19 co-expression may occur in both AML with t(8;2l) and with t(9;22) [50, 122. 123).…”

Section: Prognostic Impact Of Immunophenotyping In Amlmentioning

confidence: 99%

Immunophenotyping of Acute Leukaemias. Immunophänotypisierung akuter Leukämien

Benter¹,

Ratei²,

Wd³

2001

LaboratoriumsMedizin

Self Cite

View full text Add to dashboard Cite

For nearly 100 years the classification of blood cells and the diagnosis of leukaemia have been based on cytomorphological features after staining. Even in the era of molecular biology this is still essential. Therapy of acute myeloid leukaemia (AML) is mostly dependent on the interpretation of the morphological appearance of blasts under the microscope. Cytomorphology should also lead to a rational use of techniques like immunophenotyping, cytogenetics, fluorescence / situ hybridisation (FISH), and polymerase chain reaction (PCR).In the past two decades, the impact of immunophenotyping by flow cytometry in the diagnosis and management of acute leukaemia has expanded rapidly. This has been mainly attributed to significant advances in laser and computer technologies and the production of several hundred monoclonal antibodies (moAbs) to a variety of antinens expressed by haematopoietic cells.This review concentrates on immunophenotyping of cells from patients with acute leukaemia and shows the clinical impact on diagnostics and treatment.

show abstract

“…3) nachweisen, wobei alle 3 panmyeloischen Marker nur in knapp 55% der Fälle, zumindestens eines der 3 Antigene jedoch in dem überwiegenden Prozentsatz der AML (>97%) exprimiert werden [32,33] [36,37]. Voraussetzung für die Diagnose des MO-Subtyps, die nicht anhand morphologischer oder zytochemischer Kriterien erfolgen kann, ist neben dem immunologischen Nachweis eines panmyeloischen Antigens, z.B.…”

Section: Akute Myeloische Leukämienunclassified

Übersicht

1993

LaboratoriumsMedizin

View full text Add to dashboard Cite

Zusammenfassung: In der medizinischen Diagnostik wurde 1988 mit der Einführung der PCR-Methode eine Renaissance der Nukleihsäure-assoziierten Testsysteme eingeleitet Ein sinnvoller Einsatz dieser hocheffizienten Methodik ist momentan vor allem bei der Diagnose von Krankheitserregern angezeigt, die sich mit etablierten enzymatischen oder immunologischen Testsystemen nicht oder nur schwer nachweisen lassen. Obwohl die Diagnostik von Infektionskrankheiten als Domäne der PCR-Reaktion gehandelt wird, wurden in letzter Zeit auf diesem Sektor auch eine Reihe von alternativen Systemen zur in vitro Amplifikation von Nukleinsäuren entwickelt. Anhand ausgewählter Beispiele wird hier ein Überblick über die spezifischen Eigenschaften, die molekularbiologischen Reaktionsprinzipien, die entsprechenden Vor-und Nachteile und die damit verbundenen möglichen Indikationsgebiete dieser neuentwickelten oder verbesserten Testsysteme dargestellt. Schlüsselwörter: NukleinsäureSummary: With the introduction of PCR methodology to the area of clinical diagnostics, a strong impetus was given to the development of nucleic acid-based assays.At the moment the PCR represents a potentially powerful tool in the laboratory diagnosis of infectious diseases providing unprecedented sensitivity even to applications where there was previously no test procedure available or where the existing procedures had serious intrinsic limitations.Although the PCR-reaction remains the most widely applied amplification method, a variety of alternative Systems for the in vitro amplification of nucleic acids have been developed recently.An overview oh the specific features, molecular principles, corresponding advantages and disadvantages and the potential use of these newly developed or improved diagnostic assays is presented.

show abstract

Immunophenotype of Acute Myeloid Leukemia: Correlation with Morphological Characteristics and Therapy Response

Cited by 10 publications

References 39 publications

Identification of P‐selectin glycoprotein ligand‐1 as a useful marker in acute myeloid leukaemias

Identification of P‐selectin glycoprotein ligand‐1 as a useful marker in acute myeloid leukaemias

Immunophenotyping of Acute Leukaemias. Immunophänotypisierung akuter Leukämien

Übersicht

Contact Info

Product

Resources

About